AUTOLUS THERAPEUTICS PLC REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 6th, 2018 • Arix Bioscience PLC • Biological products, (no disgnostic substances) • England and Wales
Form of Lock-Up AgreementArix Bioscience PLC • June 11th, 2018 • Pharmaceutical preparations • New York
Autolus Limited Lock-Up AgreementArix Bioscience PLC • July 6th, 2018 • Biological products, (no disgnostic substances)
JOINT FILING AGREEMENTJoint Filing Agreement • July 6th, 2018 • Arix Bioscience PLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the American depositary shares and the ordinary shares, nominal value £0.000042 per share, of Autolus Therapeutics plc, a public limited company formed under the laws of England and Wales, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the undersigned hereby executes this Joint Filing Agreement as of July 6, 2018.
JOINT FILING AGREEMENTJoint Filing Agreement • July 20th, 2021 • Arix Bioscience PLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, $0.001 par value per share, of Imara Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to Such Statement.
JOINT FILING AGREEMENTJoint Filing Agreement • June 11th, 2018 • Arix Bioscience PLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares, par value $0.01 per share, of Iterum Therapeutics plc, a public limited company formed under the laws of Ireland, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the undersigned hereby executes this Joint Filing Agreement as of June 11, 2018.
JOINT FILING AGREEMENTJoint Filing Agreement • February 22nd, 2019 • Arix Bioscience PLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Harpoon Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the undersigned hereby executes this Joint Filing Agreement as of February 22, 2018.
JOINT FILING AGREEMENTJoint Filing Agreement • January 27th, 2020 • Arix Bioscience PLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares, par value $0.01 per share, of Iterum Therapeutics plc, a public limited company formed under the laws of Ireland, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings.
JOINT FILING AGREEMENTJoint Filing Agreement • November 2nd, 2018 • Arix Bioscience PLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of LogicBio Therapeutics, Inc,, a Delaware corporation, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the undersigned hereby executes this Joint Filing Agreement as of November 2, 2018.
JOINT FILING AGREEMENTJoint Filing Agreement • March 24th, 2020 • Arix Bioscience PLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares, par value $0.001 per share, of Imara Inc., a public limited company formed under the laws of Ireland, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings.
